MediPharm Labs Enters United States Pharmaceutical Market with Submission of FDA DMF
Cannabis Law Report
FEBRUARY 23, 2022
(TSX: LABS) (OTCQX: MEDIF ) (FSE: MLZ) (“MediPharm” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it has completed a US FDA DMF for pure natural CBD API. The DMF will enable MediPharm to supply approved API to pharmaceutical companies currently conducting late-stage research.
Let's personalize your content